ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

PKBO Peak Bio Inc (PK)

0.0225
0.00 (0.00%)
24 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Peak Bio Inc (PK) USOTC:PKBO OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.0225 0.00 00:00:00

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB

14/08/2024 10:00pm

Edgar (US Regulatory)


 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

 

 

 

 

 SEC FILE NUMBER:

 001-39951

 

 CUSIP NUMBER:

 70470P1084

 

 70470P1167

 

 

 

 

(Check One):

☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q

☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR

 

 

 

For Period Ended: June 30, 2024

 

 

 

☐ Transition Report on Form 10-K

 

 

 

☐ Transition Report on Form 20-F

 

 

 

☐ Transition Report on Form 11-K

 

 

 

☐ Transition Report on Form 10-Q

 

 

 

For the Transition Period Ended:

 

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

 


 

PART I — REGISTRANT INFORMATION

Peak Bio, Inc.

Full Name of Registrant

N/A

Former Name if Applicable

4900 Hopyard Road, Suite 100

Address of Principal Executive Office (Street and Number)

Pleasanton, CA 94588

City, State and Zip Code

PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

 

 

 

 

(a)

The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

(b)

The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

(c)

The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III — NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

(Attach extra Sheets if Needed)

The Registrant was unable to complete the filing of its Form 10-Q within the prescribed time period without unreasonable effort or expense as additional time was needed for completion of financial statement review procedures. The Registrant anticipates filing its 10-Q within the prescribed five-day extension.

 

 

 


 

PART IV — OTHER INFORMATION

 

 

 

 

 

 

 

 

 

 

 

 

 

(1)

Name and telephone number of person to contact in regard to this notification

 

 

 

 

 

 

 

 

 

Stephen LaMond

                     (650)

549-9103

 

 

(Name)

 

(Area Code)

 

(Telephone Number)

 

 

 

(2)

 

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes ☐ No ☒

 

 

 

 

 

Quarterly Report for the period ended June 30, 2024

 

 

 

(3)

 

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? Yes ☐ No ☒

 

 

 

 

 

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Peak Bio, Inc.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

Date: August 14, 2024

 

By:

/s/ Stephen LaMond

 

 

 

Name: Stephen LaMond

 

 

 

Title: Interim Chief Executive Officer (Principal Executive Officer)

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.

 

ATTENTION

Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

 



1 Year Peak Bio (PK) Chart

1 Year Peak Bio (PK) Chart

1 Month Peak Bio (PK) Chart

1 Month Peak Bio (PK) Chart

Your Recent History

Delayed Upgrade Clock